An Australian stem cell and regenerative medicine company

October 04, 2021

New Strategic Partnership with Fujifilm

Cynata and Fujifilm have entered a new and exciting strategic partnership agreement which includes detailed and agreed core terms for Fujifilm to provide clinical and commercial manufacturing services for, and supply of its Cymerus MSC products. BioWorld covered this, and Cynata’s quarter of milestones in depth here (subscriber only content)

Read Article

Read More Here

September 28, 2021

Leading peer-reviewed journal Cytotherapy publishes Cymerus™ MSC paper by Associate Professor James Chong

The paper, which summarises the results of studies led by Associate Professor James Chong (Westmead Institute for Medical Research, Sydney), validates the importance of Cymerus MSCs in treating serious and debilitating diseases and provides further recognition of Cynata’s advanced technology.

Read Article

August 13, 2021

Deal signed with TekCyte for its wound dressing technology

Cynata has signed a worldwide licence agreement with TekCyte Pty Ltd for TekCyte’s novel wound dressing technology for use in Cynata’s upcoming diabetic foot ulcer trial (short scroll down) 

Read Article

August 03, 2021

A milestone quarter for Cynata

Cynata CEO Dr Ross Macdonald appears on Kalkine TV’s “Expert Corner” to discuss the Company’s quarterly results and provides an update on its MEND trial and worldwide exclusive licence agreement with TekCyte Pty Ltd.

Watch The Interview Here

April 23, 2021

Cynata’s Cymerus™ MSCs featured in Channel 9 news article on the SCUlpTOR Phase 3 Clinical Trial in Osteoarthritis

Channel 9 Health Reporter Gabriella Rogers explores the potential therapeutic benefits of Cynata’s MSC product in this serious disease and reviews the SCULpTOR trial with Professor David Hunter

Read Article